UNSPSC 51202506: Ocrelizumab

Ocrelizumab is a pharmaceutical drug for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.

UNSPSC 51202506 Ocrelizumab, a Commodity code, has no recent state and local procurement activity that matches its scope. The code nominally identifies a disease-modifying therapy for multiple sclerosis, a single-source biopharmaceutical product requiring specialized handling, clinical protocols, and FDA-regulated distribution. The recent opportunities dataset shows no solicitations for ocrelizumab or comparable specialty pharmaceuticals under this code; instead, the tagged opportunities span naloxone distribution, emergency medical supplies for fire departments, generic multi-source pharmaceuticals through cooperative purchasing, and forensic drug reference materials—none of which are biologics or specialty therapeutics aligned with the code's nominal product.

The mismatch between code assignment and actual procurement scope signals either data-entry error or a jurisdiction's use of broad pharmaceutical codes to capture multiple unrelated product families. Without evidence of actual ocrelizumab demand in recent state or local RFPs, RFQs, or ITBs, this code shows no actionable buying signal for vendors in the specialty pharmaceutical space. Firms pursuing state and local contracts for biologics or specialty therapeutics should monitor broader pharmaceutical family codes and disease-specific procurement channels rather than rely on this commodity-level code as a demand indicator.